Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques

Joellyn McMillan, Adam Szlachetka, Tian Zhou, Brenda Morsey, Benjamin Lamberty, Shannon Callen, Nagsen Gautam, Yazen Alnouti, Benson Edagwa, Howard E. Gendelman, Howard S. Fox

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Long-acting antiretrovirals can improve therapy and prevention for HIV-1 infection. Current long-acting cabotegravir (CAB LAP) can be administered every other month. Previously, we demonstrated that a myristoylated CAB prodrug encased in poloxamer 407 provided extended plasma drug concentrations. We now demonstrate that this first-generation nanoformulated prodrug can sustain plasma CAB concentrations above the protein-adjusted 90% inhibitory concentration for 4 months in rhesus macaques. A 2.5-fold extension in CAB half-life and a 1.6-fold increase in area under the concentration-time curve were observed compared with CAB LAP.

Original languageEnglish (US)
Pages (from-to)585-588
Number of pages4
JournalAIDS
Volume33
Issue number3
DOIs
StatePublished - Mar 1 2019

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques'. Together they form a unique fingerprint.

  • Cite this